— Matinas BioPharma (NYSE: MTNB) reported loss of $0.04 per share in the fourth quarter of 2019, vs $0.03 per share loss expected.
— Initiated ENHANCE-IT study of MAT9001 against Vascepa. Topline data expected Q4 2020.
— Cash, cash equivalents and marketable securities at December 31, 2019 were approx. $27.8 million, compared to $12.4 million a year ago.
— MTNB shares ended down 2.75% in its last trading session on Friday.
Get access to timely and accurate verbatim transcripts that are published within hours of the event.
Most Popular
Adobe (ADBE) to report Q3 earnings on Sept 12. Here’s what to expect
After delivering record-high revenues in the second quarter, Adobe Inc. (NASDAQ: ADBE) is gearing up to report third-quarter results next week. The design software maker has effectively integrated advanced AI
A look at Campbell Soup’s (CPB) expectations for fiscal year 2025
Shares of Campbell Soup Company (NASDAQ: CPB) rose over 1% on Friday. The stock has gained 21% over the past three months. The company delivered sales and earnings growth for
DOCU Earnings: DocuSign Q2 2025 profit jumps on higher revenues
DocuSign, Inc. (NASDAQ: DOCU) reported a sharp increase in adjusted earnings for the second quarter of 2025. The bottom line benefitted from a 7% increase in revenues. The eSignature service
